Pancreatic Cancer Research

ResearcherNagoya University HospitalNo recent work listed

Hidemi Goto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8389-1416; OpenAlex author ID A5071579046. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 2 papers

Papers 11

  1. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  2. ATAD2 is associated with malignant characteristics of pancreatic cancer cells. Co-author DOI 10.3892/ol.2019.9960↗
  3. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  4. Natural history of pancreatic cystic lesions: A multicenter prospective observational study for evaluating the risk of pancreatic cancer. Last author DOI 10.1111/jgh.13967↗
  5. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. Last author DOI 10.1186/s12885-018-4453-z↗
  6. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention. Co-author DOI 10.1111/jgh.13172↗
  7. Treatment with near-infrared radiation promotes apoptosis in pancreatic cancer cells. Co-author DOI 10.3892/ol.2015.3399↗
  8. Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis. Co-author DOI 10.1155/2012/510397↗
  9. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Co-author DOI 10.1007/s00280-010-1531-6↗
  10. How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple … First author DOI 10.1097/mpa.0b013e3181fe4031↗
  11. Intravenous fluid therapy successfully prevents renal injury by gemcitabine in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318214efce↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshiki Hirooka · 8 shared papers, 2011–2019 · strength 0.50
  2. Eizaburo Ohno · 6 shared papers, 2011–2019 · strength 0.33
  3. Hiroki Kawashima · 5 shared papers, 2011–2019 · strength 0.27
  4. Takuya Ishikawa · 3 shared papers, 2018–2019 · strength 0.21
  5. Yasuhiro Kodera · 3 shared papers, 2018–2019 · strength 0.21
  6. Tomohiko Obayashi · 2 shared papers, 2015–2019 · strength 0.16
  7. Takeshi Senga · 2 shared papers, 2015–2019 · strength 0.16
  8. Yukihiro Yokoyama · 3 shared papers, 2012–2019 · strength 0.16
  9. Senju Hashimoto · 3 shared papers, 2011–2018 · strength 0.13
  10. Masamichi Hayashi · 2 shared papers, 2018–2019 · strength 0.13
  11. Yukio Ando · 2 shared papers, 2018–2019 · strength 0.13
  12. Masato Nagino · 2 shared papers, 2018–2019 · strength 0.13
  13. Nao Takano · 2 shared papers, 2018–2019 · strength 0.13
  14. Suguru Yamada · 2 shared papers, 2018–2019 · strength 0.13
  15. Shinji Naganawa · 2 shared papers, 2018–2019 · strength 0.13
  16. Junpei Yamaguchi · 2 shared papers, 2018–2019 · strength 0.13
  17. Osamu Maeda · 2 shared papers, 2018–2019 · strength 0.13
  18. Tsutomu Fujii · 2 shared papers, 2018–2019 · strength 0.13
  19. Hiroyuki Sugimoto · 2 shared papers, 2016–2018 · strength 0.11
  20. Shigeru B. H. Ko · 3 shared papers, 2011–2012 · strength 0.11
  21. Nairong Liu · 1 shared paper, 2019 · strength 0.11
  22. Hideki Kasuya · 1 shared paper, 2018 · strength 0.07
  23. Masaya Suenaga · 1 shared paper, 2019 · strength 0.07
  24. Fuminori Sonohara · 1 shared paper, 2019 · strength 0.07
  25. Akihiro Hirakawa · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.